Roches cancerpiller missade fas III-målet – aktien backar

En tablettbehandling mot bröstcancer, som enligt Roche har potential att bli en ny standardbehandling, missade överraskande sitt primära effektmått i sen klinisk fas.

By Anders Göransson

March 9, 2026 10:29 AM

I fas III-studien Persevera prövades läkemedelskandidaten giredestrant i kombination med palbociclib som behandling för i ER-positiv, HER2-negativ avancerad bröstcancer.

Roche meddelar nu att man inte nådde sitt primära mål om statistiskt signifikant förbättring i progressionsfri överlevnad jämfört med standardbehandlingen, även om viss numerisk förbättring observerades.

1 month free trial

Get access to all content on Life Science Focus

No commitment or card information required

Try Life Science Focus now

Already a subscriber? Log In

Applies to personal subscription only.

{{ comments.count === 1 ? '1 comment' : comments.count > 1 ? '{0} comments'.replace('{0}', comments.count) : 'Write a comment' }}

By submitting the comment you accept the terms. See terms

Good comment behavior

Keep a good tone in your comments, avoid personal attacks and posts of marketing character. Apply only link on your comment if it is relevant to the debate.

Be aware that the debates are moderated by the portal's editorial team.

The comment has been created.

Your comment will not be visible until you activate it. In a few moments you will receive an email where you must click on a link to activate your comment.

Yes please, I would like to receive Life Science Focuss newsletter Read cookie and data policy.

Yes please, I would like to receive marketing, offers, surveys, etc. from Life Science Focus Read cookie and data policy.

{{ window.visitor.corporateClient.name }}

Corporate solution

{{ window.visitor.ipAccess.corporateClient.name }}

{{ window.visitor.corporateClient.name }}

Roches cancerpiller missade fas III-målet – aktien backar

A new name for a broader outlook

Novartis expands brain‑delivery push with Sironax deal

Novo Nordisk enters billion-dollar collaboration with Orbis Medicines

Rarity Bioscience targets hidden disease signal with new test

Stem cell setback in infant heart condition

Bavarian Nordic names Tarja Stenvall new CEO

Nautilus Fluidics Simulation Application finns nu tillgänglig

SGS – Accelerate Your Path to the EU Market with IVDR Certification

Upcoming Training: IEC 62366 Medical Device Usability

ZEISS announces commercial availability of bitoric hydrophobic monofocal IOL

Medtech Compliance Forum: Explore This Year's Programme Tracks

Introducing ZEISS VersaXRM 5 Insight

Meet ZEISS Microscopy at ECP 2026 in Stockholm

Kompakt gasflödesreglering för trånga installationer

Need support with EUDAMED?

Smart visionteknik ger robotar rätt förutsättningar i logistiken

Turning insights into impact

Improved flexibility for CTIS submissions